Leaders in RNA and DNA Testing
Liquid Biopsy Labs
Liquid Biopsy Labs offers the most comprehensive cancer genetic testing – DNA & RNA – with liquid biopsy and tissue.
ACCURATE, COMPREHENSIVE, FAST
What Makes our Tests Unique
Liquid Biopsy Labs is a platform providing patients, doctors, and researchers with high-precision liquid biopsy testing and tissue sequencing (DNA & RNA) to detect and monitor cancer at the molecular level – offering the most accurate, thorough, and fast detection, and treatment monitoring available through medical science today.
- Unique liquid biopsy tests
Designed to deliver unheard-of precision in screening and treatment monitoring. - Every test is personalized
We measure not just tumor DNA, but the ratio of cancerous to non-cancerous exosomes, ensuring the changes we target are truly driving the cancer. - Earliest cancer detection possible
Our tests detect tumor-causing molecular changes at levels as low as ~0.02% of total DNA – enabling detection before imaging may pick up a tumor. - Outcome-oriented
Our NGS cancer tests are designed to maximize correct treatment matching, reduce wasted time, improve survival and reduce side-effects.
ALWAYS AHEAD OF THE CURVE
Our Mission
Precision oncology represents the most advanced and compassionate approach to cancer care today. By understanding the unique molecular makeup of each patient’s cancer, Liquid Biopsy Labs helps transform overwhelming uncertainty into clarity and action.
Our mission is not only to provide the most accurate testing and thorough analysis available, but also to ensure that this information translates into real-world access and improved outcomes.
Precision Cancer Medicine
Our Expert Team
Liquid Biopsy Labs is fueled by a team of interdisciplinary Oncogenomic Specialists, Cancer Research Scientists, Data Analysts, Research & Design Experts, and Regulatory Affairs Specialists. Our primary objective is to develop leading-edge Next-Generation Sequencing cancer tests and make the results actionable to patients, doctors, and researchers on the front-lines.
RECOGNIZED BY ASCO AND ESMO
Publications
Liquid Biopsy Labs’ groundbreaking LRNA Liquid Biopsy has been recognized by leading international oncology congresses.
We are pleased to share that Liquid Biopsy Labs’ Liquid RNA abstract was selected for presentation at the ESMO Targeted Anticancer Therapies Congress 2026. Our co-founder and CEO, Michelle Morand presented our abstract in Paris on March 16th.
You can see our L-RNA abstract here – just search for Poster 139P –“Clinical Performance Of Novel Exosomal Liquid RNA Biopsy Assay In Lung Cancer Segment.”
Liquid Biopsy Labs’ Liquid RNA abstract was also selected at ASCO GI 2026 conference, in San Francisco, California, January 2026. See the abstract: ”Clinical performance of liquid RNA (L-RNA) biopsy in a gastrointestinal cancer segment.’’
EARLY DETECTION, Recommendations, MONITORING
Our Services
With over a decade of experience in Next-Generation Sequencing, Liquid Biopsy Labs is known for our groundbreaking NGS cancer tests, sophisticated and rapid analysis, and ability to ensure that any results are easily and immediately actionable to patients and doctors on the front-lines.
Our team has served cancer patients, doctors, and labs around the world, including Europe, Asia, and North America; and we’ve received patient referrals from leading institutions including the Mayo Clinic and Johns Hopkins.
Get your questions answered live!
Join our drop-in Zoom sessions with our co-founder, Michelle Morand.